Production of recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system for biotherapy of GMCSF-receptor positive hematologic malignancies

被引:11
作者
Williams, MD
Rostovtsev, A
Narla, RK
Uckun, FM
机构
[1] Alexander Parker Pharmaceut Inc, Dept Prot Engn, Roseville, MN 55113 USA
[2] Wayne Hughes Inst, Biotherapy Program, St Paul, MN 55113 USA
[3] Wayne Hughes Inst, Dept Expt Oncol, St Paul, MN 55113 USA
关键词
D O I
10.1006/prep.1998.0900
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The fusion toxin DT(ct)GMCSF has been constructed by genetically replacing the native receptor-binding domain of diphtheria toxin (DT) with human granulocyte-macrophage colony stimulating factor (GMCSF). This recombinant fusion toxin preserves the catalytic (c) and membrane translocation (t) domains of DT and includes a sterically neutral peptide linker separating the toxin and growth factor domains. Previous work using DTct-GMCSF produced in Escherichia coli has shown that this chimeric toxin is selectively cytotoxic to GMCSF receptor (R)-positive acute myeloid leukemia (AML) cells both in vitro and in vivo. Its clinical development has been hampered due to very low expression levels, requirements for solubilization with guanidine hydrochloride and subsequent refolding, and concerns about bacterial endotoxin contamination. These difficulties prompted us to investigate the utility of a baculovirus/ insect cell expression system for the production of DTct-GMCSF. Here, we report that a soluble form of DT(ct)G-GMCSF can be produced in the baculovirus expression vector system (BEVS) and purified to homogeneity by column chromatography. The BEVS-derived DT(ct)G-MCSF fusion toxin caused apoptotic death in GMCSF-R-positive human AML cells at nanomolar concentrations. In contrast to the 100 mu g/L yields of pwified DT(ct)GMCSF obtained from E. coli, the BEVS allows us to routinely generate 8-10 mg/L of purified DT(ct)GMCSF. This increased capacity provided by the BEVS for the production of DT(ct)GMCSF makes it now possible to obtain sufficient quantities to carry out preclinical and clinical trials. To our knowledge, this is the first report of the successful utilization of the BEVS for producing a therapeutic fusion toxin. (C) 1998 Academic Press.
引用
收藏
页码:210 / 221
页数:12
相关论文
共 48 条
[21]  
LEMAISTRE CF, 1993, CANCER RES, V53, P3930
[22]  
LEMAISTRE CF, 1992, BLOOD, V79, P2547
[23]  
LeMaistre CF, 1998, BLOOD, V91, P399
[24]   EFFICIENT GENERATION OF INFECTIOUS RECOMBINANT BACULOVIRUSES BY SITE-SPECIFIC TRANSPOSON-MEDIATED INSERTION OF FOREIGN GENES INTO A BACULOVIRUS GENOME PROPAGATED IN ESCHERICHIA-COLI [J].
LUCKOW, VA ;
LEE, SC ;
BARRY, GF ;
OLINS, PO .
JOURNAL OF VIROLOGY, 1993, 67 (08) :4566-4579
[25]  
McCarthy NJ, 1998, CURR TOP DEV BIOL, V36, P259
[26]  
Meneghetti C M, 1992, Targeted Diagn Ther, V7, P395
[27]   GENETIC CONSTRUCTION, EXPRESSION, AND MELANOMA-SELECTIVE CYTOTOXICITY OF A DIPHTHERIA TOXIN-RELATED ALPHA-MELANOCYTE-STIMULATING HORMONE FUSION PROTEIN [J].
MURPHY, JR ;
BISHAI, W ;
BOROWSKI, M ;
MIYANOHARA, A ;
BOYD, J ;
NAGLE, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (21) :8258-8262
[28]   HIGH-RISK OF EARLY RESISTANT RELAPSE FOR LEUKEMIC PATIENTS WITH PRESENCE OF MULTIDRUG RESISTANCE ASSOCIATED P-GLYCOPROTEIN POSITIVE CELLS IN COMPLETE REMISSION [J].
MUSTO, P ;
MELILLO, L ;
LOMBARDI, G ;
MATERA, R ;
DIGIORGIO, G ;
CAROTENUTO, M .
BRITISH JOURNAL OF HAEMATOLOGY, 1991, 77 (01) :50-53
[29]  
MYERS DE, 1995, P NATL ACAD SCI USA, V92, P9576
[30]  
O'Reilly D.R., 1992, BACULOVIRUS EXPRESSI